Innate Pharma (IPHA) Price Target: AI vs Analyst Consensus
Our AI model gives Innate Pharma (IPHA) a 6-month price target of $2.02, representing 4.7% potential downside from the current price of $2.12. The forecast combines financial fundamentals, technical analysis, and 25+ alternative data signals, including hiring trends, web traffic, employee sentiment, and social media activity. Innate Pharma’s current AI Score is 45/100 (Neutral).
What’s Driving the IPHA Price Target
These are the signals feeding Innate Pharma’s AI price target — spanning financial fundamentals, technical analysis, and alternative data — grouped by their recent direction. Improving signals tend to support a higher target; declining signals weigh on it.
IPHA Stock Forecast for 2026
Our AI model gives Innate Pharma (IPHA) a 6-month price target of $2.02 — 4.7% downside from the current price of $2.12 — implying a decline toward that level through the rest of 2026. The target updates daily as new IPHA financial, technical, and alternative-data signals come in.
IPHA Price Prediction for 2027–2030
AltIndex does not publish a multi-year model — alternative data is most predictive over the next 6–12 months. Extending the current trajectory as a simple linear extrapolation projects IPHA toward $1.44 by 2030, but long-range estimates carry far more uncertainty and should be treated as directional only. The more reliable signal is whether Innate Pharma’s AI Score and the drivers above keep improving over time.
Innate Pharma (IPHA) Monthly Price Forecast
| Month | Forecast | vs Current |
|---|---|---|
| Sep 2026 | $2.10 | -0.8% |
| Oct 2026 | $2.09 | -1.6% |
| Nov 2026 | $2.07 | -2.4% |
| Dec 2026 | $2.05 | -3.1% |
| Jan 2027 | $2.04 | -3.9% |
| Feb 2027 | $2.02 | -4.7% |
Straight-line projection from the latest price ($2.12) toward our 6-month AI target of $2.02. An estimate, not a month-by-month model.
See how AltIndex’s AI Score picks have performed →Similar companies
View All →
Frequently Asked Questions: Innate Pharma Price Prediction
On August 18, Innate Pharma (IPHA) was assigned a Hold with a target price of $2.02. This signal was predicated on several factors, including concerns regarding the company's financial fundamentals, a worryingly low business outlook across the company's employees, and a long-term decrease in Twitter followers.
The conviction in the pick is low due to the limited amount of alternative data available.
Based on Alternative Data, Innate Pharma is a hold.
Alternative data suggests that it's recommended to approach Innate Pharma (IPHA) with caution. While there are positive indicators, the overall assessment suggests a hold based on Alternative Data analysis. However, this information should not be considered financial advice.
With an AI score of 45, the IPHA stock forecast suggests stability.
To predict the price for IPHA in 2027, we can extrapolate the AI price target. This approach projects IPHA's price to reach $2.04.
To predict the price for IPHA in 2030, we can again extrapolate the AI price target. This approach projects IPHA's price to reach $1.44.
When predicting the price for IPHA, our approach incorporates multiple scores assessing different aspects of the company. The Brand score measures growth and engagement across social media channels, indicating audience reach. The Employee score evaluates workforce health, considering job postings, business outlook, and employee ratings. The Customer score examines engagement on websites, app downloads, and sentiment in stock forums. Lastly, the Fundamental score analyzes financial statements and analyst ratings. By evaluating this data, we gain a holistic view of the company's performance, enabling more informed price predictions.
Based on technical analysis of how the price has moved over the last 6 months, the likelihood of the price going up tomorrow is 23%. Note that this is a simplistic analysis and should be used with caution, as prices are influenced by a myriad of factors.
Know the moment Innate Pharma’s price target changes
Get IPHA alerts
